This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
7
2 mg per day
conversion to psychosis
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.